New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
06:35 EDTISISIsis may have most attractive pipeline in biotech, says Piper Jaffray
Piper Jaffray believes Isis Pharmaceuticals' wholly owned and partnered assets could represent the most attractive and undervalued pipeline in biotech. The firm reiterates an Overweight rating on the stock with a $42 price target following the company's R&D day.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
19:43 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
April 8, 2015
16:11 EDTISISRegulus files to sell 3.3M shares for Isis Pharmaceuticals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use